BRPI0509331B8 - uso de uma composição de ligação de sódio - Google Patents
uso de uma composição de ligação de sódioInfo
- Publication number
- BRPI0509331B8 BRPI0509331B8 BRPI0509331A BRPI0509331A BRPI0509331B8 BR PI0509331 B8 BRPI0509331 B8 BR PI0509331B8 BR PI0509331 A BRPI0509331 A BR PI0509331A BR PI0509331 A BRPI0509331 A BR PI0509331A BR PI0509331 B8 BRPI0509331 B8 BR PI0509331B8
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- pharmaceutical compositions
- binding composition
- sodium binding
- sodium
- Prior art date
Links
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229910052708 sodium Inorganic materials 0.000 title abstract 3
- 239000011734 sodium Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000028208 end stage renal disease Diseases 0.000 abstract 1
- 201000000523 end stage renal failure Diseases 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F120/04—Acids; Metal salts or ammonium salts thereof
- C08F120/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F128/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur
- C08F128/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfur by a bond to sulfur
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/814,527 US7854924B2 (en) | 2004-03-30 | 2004-03-30 | Methods and compositions for treatment of ion imbalances |
US10/813,872 US8282960B2 (en) | 2004-03-30 | 2004-03-30 | Ion binding compositions |
US10/814,749 US8192758B2 (en) | 2004-03-30 | 2004-03-30 | Ion binding compositions |
US10/965,274 US7488495B2 (en) | 2004-03-30 | 2004-10-13 | Ion binding polymers and uses thereof |
PCT/US2005/011010 WO2005094384A2 (en) | 2004-03-30 | 2005-03-30 | Methods and compositions for treatment of ion imbalances |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0509331A BRPI0509331A (pt) | 2007-09-04 |
BRPI0509331B1 BRPI0509331B1 (pt) | 2018-11-27 |
BRPI0509331B8 true BRPI0509331B8 (pt) | 2021-05-25 |
Family
ID=35054544
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509366A BRPI0509366B8 (pt) | 2004-03-30 | 2005-03-30 | composição farmacêutica, kit farmacêutico, e, uso de uma composição farmacêutica |
BRPI0509365A BRPI0509365B8 (pt) | 2004-03-30 | 2005-03-30 | composição farmacêutica, kit farmacêutico, e, uso da referida composição |
BRPI0509331A BRPI0509331B8 (pt) | 2004-03-30 | 2005-03-30 | uso de uma composição de ligação de sódio |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509366A BRPI0509366B8 (pt) | 2004-03-30 | 2005-03-30 | composição farmacêutica, kit farmacêutico, e, uso de uma composição farmacêutica |
BRPI0509365A BRPI0509365B8 (pt) | 2004-03-30 | 2005-03-30 | composição farmacêutica, kit farmacêutico, e, uso da referida composição |
Country Status (12)
Country | Link |
---|---|
US (14) | US7776319B2 (pt) |
EP (3) | EP1732516B1 (pt) |
JP (3) | JP4964122B2 (pt) |
KR (3) | KR101153035B1 (pt) |
AU (3) | AU2005228696B2 (pt) |
BR (3) | BRPI0509366B8 (pt) |
CA (3) | CA2557848C (pt) |
DE (1) | DE112005000730B4 (pt) |
GB (3) | GB2430624B (pt) |
MX (1) | MXPA06011270A (pt) |
PL (1) | PL1732523T3 (pt) |
WO (3) | WO2005094384A2 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7381428B2 (en) | 2003-08-26 | 2008-06-03 | Shire International Licensing B.V. | Stabilized lanthanum carbonate compositions |
CZ17621U1 (cs) | 2003-08-26 | 2007-06-25 | Shire Holdings Ag | Farmaceutický prostredek zahrnující slouceniny lanthanu |
DE112005000708B4 (de) * | 2004-03-30 | 2017-12-21 | Relypsa, Inc. (n.d.Ges.d. Staates Delaware) | Ionen bindende Zusammensetzung |
CA2557848C (en) * | 2004-03-30 | 2013-12-10 | Ilypsa, Inc. | Ion binding compositions |
BRPI0616604A2 (pt) | 2005-09-30 | 2012-12-25 | Ilypsa Inc | mÉtodo para remover e composiÇço para seletivamente remover Íon de potÁssio do trato gastrintestinal de um mamÍfero, mÉtodo para seletivamente remover Íon de potÁssio de um meio-ambiente, composiÇço farmacÊutica, partÍcula de nécleo-envoltàrio, e, usos de uma partÍcula de nécleo-envoltàrio e de uma composiÇço farmacÊutica |
WO2007038801A2 (en) * | 2005-09-30 | 2007-04-05 | Ilypsa, Inc. | Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof |
CA2624112A1 (en) * | 2005-09-30 | 2007-04-05 | Ilypsa, Inc. | Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom |
CN100398112C (zh) * | 2006-03-24 | 2008-07-02 | 辽宁诺康生物制药有限责任公司 | 一种治疗血磷酸盐过多症的药物及其制备方法 |
ES2708851T3 (es) * | 2006-10-06 | 2019-04-11 | Bionet Pharma Gmbh | Un implante del núcleo pulposo espinal |
WO2008078797A1 (ja) * | 2006-12-26 | 2008-07-03 | Otsuka Pharmaceutical Factory, Inc. | ナトリウム吸収阻害剤、カリウム吸収阻害剤およびリン吸収阻害剤、並びにそれを含む予防剤、治療剤および食品 |
EP2108661A1 (en) * | 2006-12-26 | 2009-10-14 | Chisso Corporation | Metal salt of crosslinked cellulose derivative |
MX2009011898A (es) * | 2007-05-04 | 2009-11-18 | Ironwood Pharmaceuticals Inc | Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido. |
CA2697803A1 (en) * | 2007-08-29 | 2009-03-05 | Sorbent Therapeutics, Inc. | Absorbent polymeric compositions with varying counterion content and their methods of preparation and use |
JP5294681B2 (ja) * | 2008-04-28 | 2013-09-18 | 東京エレクトロン株式会社 | 基板処理装置及びその基板搬送方法 |
WO2010022381A1 (en) * | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
AU2013204879B2 (en) * | 2008-08-22 | 2015-10-29 | Vifor (International) Ltd. | Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia |
WO2010022383A2 (en) | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia |
WO2010022380A2 (en) * | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Linear polyol stabilized polyfluoroacrylate compositions |
US20100111892A1 (en) * | 2008-08-22 | 2010-05-06 | Relypsa, Inc. | Crosslinked polyfluoroacrylic acid and processes for the preparation thereof |
US20120107381A1 (en) * | 2009-05-13 | 2012-05-03 | Relypsa, Inc. | Powder formulations of potassium-binding active agents |
PT2550305T (pt) | 2010-03-20 | 2018-04-20 | Relypsa Inc | Processo contínuo para preparar partículas de polifluoroacrilato |
US9314523B2 (en) | 2010-09-21 | 2016-04-19 | Elwha Llc | Ingestible salt grabber |
EP3246287A1 (en) | 2011-02-11 | 2017-11-22 | ZS Pharma, Inc | Microporous zirconium silicate for the treatment of hyperkalemia |
CN108658768A (zh) | 2011-06-27 | 2018-10-16 | 瑞立普萨公司 | 丙烯酸酯及衍生物的氟化 |
CN110028603A (zh) | 2011-06-27 | 2019-07-19 | 瑞立普萨公司 | 用于将聚合酯转化为聚合酸的方法 |
US9943637B2 (en) | 2012-06-11 | 2018-04-17 | ZS Pharma, Inc. | Microporous zirconium silicate and its method of production |
CN104968336A (zh) * | 2012-07-11 | 2015-10-07 | Zs制药公司 | 用于治疗高钙血症患者高钾血症的微孔硅酸锆以及用于治疗高钾血症的改进的含钙组合物 |
IN2015DN01369A (pt) * | 2012-07-19 | 2015-07-03 | Relypsa Inc | |
CA2879493C (en) | 2012-08-09 | 2018-08-28 | Dpx Fine Chemicals Austria Gmbh & Co Kg | Process for drying polymeric materials |
KR20150088243A (ko) * | 2012-10-08 | 2015-07-31 | 리립사, 인크. | 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제 |
US10695365B2 (en) | 2012-10-22 | 2020-06-30 | ZS Pharma, Inc. | Microporous zirconium silicate for the treatment of hyperkalemia |
JP6423795B2 (ja) | 2012-10-22 | 2018-11-14 | ズィーエス・ファーマ,インコーポレーテッド | 高カリウム血症を治療するための微多孔性ケイ酸ジルコニウム |
EP3578185B1 (en) | 2013-06-05 | 2020-08-05 | Tricida Inc. | Proton-binding polymers for oral administration |
EP3842806A1 (en) * | 2013-12-11 | 2021-06-30 | Kagami Inc. | Marker for early diagnosis of kidney failure |
US9675636B2 (en) * | 2014-01-31 | 2017-06-13 | University Of Kansas | Micelle sequestering polymers |
JP6468780B2 (ja) * | 2014-09-30 | 2019-02-13 | 積水化成品工業株式会社 | 中空樹脂粒子及びその製造方法 |
BR122021001914B1 (pt) | 2014-12-10 | 2024-02-27 | Tricida, Inc | Processo para preparação de um polímero de amina reticulada |
AR103250A1 (es) * | 2014-12-23 | 2017-04-26 | Ardelyx Inc | Composiciones y métodos para tratar la hipercalemia |
US9592253B1 (en) | 2015-10-14 | 2017-03-14 | ZS Pharma, Inc. | Extended use zirconium silicate compositions and methods of use thereof |
ITUB20159278A1 (it) | 2015-12-23 | 2017-06-23 | Rjw Pharma Llc | Procedimento per la sintesi di patiromer |
US11406661B2 (en) | 2016-05-06 | 2022-08-09 | Tricida, Inc. | HCl-binding compositions for and methods of treating acid-base disorders |
JP2018125951A (ja) * | 2017-01-31 | 2018-08-09 | 日本電産株式会社 | モータ及びそれを備えた送風装置 |
EP3703706A4 (en) | 2017-11-03 | 2022-04-27 | Tricida Inc. | COMPOSITIONS AND METHOD FOR TREATING ACID-BASE DISORDERS |
JP7365631B2 (ja) * | 2019-09-02 | 2023-10-20 | 国立大学法人福井大学 | ホスホン酸又はホスホン酸エステル構造を有するコア-シェル型高分子微粒子、粒子分散液、成形体及び前記微粒子の製造方法 |
CN113244339B (zh) * | 2021-06-04 | 2021-09-24 | 南京厚生药业有限公司 | 一种用于高脂血症的考来烯胺散及其制备方法 |
US20240139234A1 (en) * | 2021-11-17 | 2024-05-02 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Pharmaceutical polymer for treating hyperkalemia and preparation method thereof |
WO2024035944A1 (en) * | 2022-08-12 | 2024-02-15 | University Of Kansas | Extraction of critical minerals using polyanions |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2340111A (en) * | 1942-07-03 | 1944-01-25 | Gen Electric | Process for removing cations from liquid media |
US2611730A (en) | 1950-09-02 | 1952-09-23 | Simth Kline & French Lab | Medical preparation for reducing the body level of sodium |
US2798053A (en) * | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US3499960A (en) | 1965-01-25 | 1970-03-10 | Merck & Co Inc | Palatable coated particles of an anion exchange resin |
FR2171934B1 (pt) * | 1972-02-16 | 1974-09-13 | Rhone Poulenc Sa | |
US3974272A (en) | 1972-09-01 | 1976-08-10 | Merck & Co., Inc. | Palatable cholestyramine coacervate compositions |
US4143130A (en) | 1977-08-29 | 1979-03-06 | Warren-Teed Laboratories, Inc. | Method for treating kidney stones |
US4470975A (en) | 1977-10-21 | 1984-09-11 | The Johns Hopkins University | Method and composition for the elimination of water from an animal body |
US4380590A (en) | 1978-09-19 | 1983-04-19 | Rohm And Haas Company | Emulsion copolymer cation exchange resins |
US4191812A (en) * | 1978-09-19 | 1980-03-04 | Rohm And Haas Company | Ion exchange process involving emulsion ion exchange resins |
SE8003805L (sv) | 1980-05-21 | 1981-11-22 | Haessle Ab | En farmaceutisk beredning med forbettrade utlosningsegenskap |
US4362711A (en) | 1980-07-11 | 1982-12-07 | Evreka Inc. | Blood cholesterol level reducing agent and method |
DE3031737A1 (de) | 1980-08-22 | 1982-04-01 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von perlpolymerisaten einheitlicher teilchengroesse |
DE3149136A1 (de) | 1981-12-11 | 1983-06-23 | Robert Bosch Gmbh, 7000 Stuttgart | Einrichtung zur regelung des kraftstoff-luftverhaeltnisses bei brennkraftmaschinen |
JPS6090243A (ja) | 1983-10-25 | 1985-05-21 | Nitto Boseki Co Ltd | 小球状モノアリルアミン橋かけ重合体の製造方法 |
US5238924A (en) | 1984-05-03 | 1993-08-24 | Merck & Co., Inc. | Treatment of renal diseases with ace inhibitors |
KR920006865B1 (ko) | 1984-05-18 | 1992-08-21 | 워싱톤 유니버시티 테크놀러지 어소우시에이츠 인코오퍼레이티드 | 입자나 액적을 피복하는 방법과 장치 |
US4747881A (en) | 1985-02-05 | 1988-05-31 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
US5186937A (en) | 1985-06-07 | 1993-02-16 | A.E.C. Societe De Chimie Organique Et Biologique | Composition for feeding ruminants |
IT1190349B (it) | 1986-06-16 | 1988-02-16 | Prodotti Formenti Srl | Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle |
JPS63218713A (ja) | 1987-02-17 | 1988-09-12 | Daikin Ind Ltd | α−フルオロアクリル酸系重合体ならびに用途 |
US4837015A (en) | 1987-03-05 | 1989-06-06 | Carolina Medical Products Company, Inc. | Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels |
US5210079A (en) * | 1988-01-07 | 1993-05-11 | E. I. Du Pont De Nemours And Company | Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists |
FR2634377B1 (fr) | 1988-06-30 | 1991-09-27 | Cortial | Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif |
GB8817015D0 (en) | 1988-07-16 | 1988-08-17 | Reckitt & Colmann Prod Ltd | Method of treatment |
GB8829088D0 (en) | 1988-12-13 | 1989-01-25 | Smith Kline French Lab | Compounds |
US5236701A (en) | 1989-07-19 | 1993-08-17 | Lowchol Scientific Inc. | Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol |
DE3928990A1 (de) | 1989-09-01 | 1991-03-07 | Bayer Ag | Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten |
US5112993A (en) | 1989-11-14 | 1992-05-12 | E. I. Du Pont De Nemours And Company | Process for the preparation of difluoromaleic anhydride |
US5091175A (en) | 1990-05-14 | 1992-02-25 | Erbamont Inc. | Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane |
ES2070307T3 (es) | 1990-07-04 | 1995-06-01 | Marcin Krotkiewski | Una preparacion para el tratamiento de la hipertension. |
IE914179A1 (en) | 1990-12-07 | 1992-06-17 | Ici Plc | Nitrogen derivatives |
US5162110A (en) * | 1990-12-19 | 1992-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Binding theophylline to ion exchange resins |
US5281631A (en) | 1991-12-20 | 1994-01-25 | Arch Development Corp. | Phosphonic acid based ion exchange resins |
DK0563731T3 (da) * | 1992-03-28 | 1996-03-18 | Hoechst Ag | Lægemidler indeholdende polyhydromethylenderivater, fremgangsmåde til deres fremstilling og deres anvendelse |
ATE168707T1 (de) | 1992-08-20 | 1998-08-15 | Du Pont | Vernetzte polymerische ammoniumsalze |
AU6818894A (en) | 1993-05-20 | 1994-12-20 | Geltex Pharmaceuticals, Inc. | Process for adjusting ion concentration in a patient and compositions therefor |
US5487888A (en) | 1993-05-20 | 1996-01-30 | Geltex, Inc. | Iron-binding polymers for oral administration |
US5618530A (en) | 1994-06-10 | 1997-04-08 | Geltex Pharmaceuticals, Inc. | Hydrophobic amine polymer sequestrant and method of cholesterol depletion |
US5607669A (en) | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
ATE162958T1 (de) | 1993-11-25 | 1998-02-15 | Salternate B V | Teilchen zum binden monovalenten kationen und ihre verwendung |
TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
US5824339A (en) | 1995-09-08 | 1998-10-20 | Takeda Chemical Industries, Ltd | Effervescent composition and its production |
US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
JP3885130B2 (ja) | 1996-06-11 | 2007-02-21 | 株式会社大塚製薬工場 | グアニジノ化合物低下剤並びに水分及びカリウムイオン吸着剤 |
ES2325046T3 (es) | 1996-06-26 | 2009-08-24 | The Board Of Regents, The University Of Texas System | Formulacion farmaceutica extruible por fusion en caliente. |
US6491903B1 (en) * | 1996-06-27 | 2002-12-10 | Washington University | Particles comprising amphiphilic copolymers |
US6623759B2 (en) | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
US5935599A (en) | 1996-10-28 | 1999-08-10 | The Board Of Trustees Of The University Of Illinois | Polymer-associated liposomes for drug delivery and method of manufacturing the same |
JPH10130154A (ja) | 1996-10-29 | 1998-05-19 | Otsuka Pharmaceut Factory Inc | 腎疾患患者用延命率改善薬 |
BR9813808A (pt) | 1997-12-19 | 2002-05-28 | Smithkline Beecham Corp | Processo para produção de comprimidos para dispersão na mordida |
US6280717B1 (en) | 1998-07-31 | 2001-08-28 | Nikken Chemicals Co., Ltd. | Cation exchange resin preparation |
US6294163B1 (en) | 1998-10-02 | 2001-09-25 | Geltex Pharmaceuticals, Inc. | Polymers containing guanidinium groups as bile acid sequestrants |
CZ20011590A3 (cs) | 1998-11-06 | 2003-01-15 | G. D. Searle & Co. | Léčivo pro léčení kardiovaskulárních poruch a kompozice s obsahem inhibitoru enzymu konvertujícího angiotensin, antagonisty aldosteronu, kličkového diuretika a digoxinu |
JP2002534374A (ja) * | 1999-01-07 | 2002-10-15 | エラン コーポレーシヨン ピーエルシー | 多粒子経口用量形態 |
US6558665B1 (en) | 1999-05-18 | 2003-05-06 | Arch Development Corporation | Encapsulating particles with coatings that conform to size and shape of the particles |
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
US20020054903A1 (en) * | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
WO2001051063A1 (fr) | 2000-01-14 | 2001-07-19 | Otsuka Pharmaceutical Factory, Inc. | Inhibiteurs de l'absorption de l'ion sodium, et agents prophylactiques ou therapeutiques et produits alimentaires renfermant lesdits inhibiteurs |
FR2812632B1 (fr) | 2000-08-07 | 2003-03-07 | Solvay | Procede pour la synthese de composes fluoroorganiques |
JP2004517066A (ja) | 2000-11-20 | 2004-06-10 | ダウ グローバル テクノロジーズ インコーポレイティド | 水吸収性ポリマーの生体内での使用 |
US20040105895A1 (en) | 2001-02-06 | 2004-06-03 | Ash Stephen R | Monovalent-selective cation exchangers as oral sorbent therapy |
US7033639B2 (en) | 2001-05-16 | 2006-04-25 | Rohm And Haas Company | Polyaniline coating composition |
US6881484B2 (en) | 2001-05-30 | 2005-04-19 | Mitsubishi Kagaku Iatron, Inc. | Core-shell particle including signal-generating substance enclosed therein and process for producing the same |
JP2004149525A (ja) | 2002-10-09 | 2004-05-27 | Sekisui Chem Co Ltd | カリウムイオン吸着剤及びその製造方法、並びに高カリウム血症治療剤 |
US7060188B2 (en) * | 2003-02-25 | 2006-06-13 | Finnfeeds Finland Oy | Separation system and process |
EP1699442A2 (en) | 2003-12-31 | 2006-09-13 | Genzyme Corporation | Enteric coated aliphatic amine polymer bile acid sequestrants |
US7429394B2 (en) * | 2004-03-30 | 2008-09-30 | Relypsa, Inc. | Ion binding compositions |
CA2557848C (en) * | 2004-03-30 | 2013-12-10 | Ilypsa, Inc. | Ion binding compositions |
US7854924B2 (en) * | 2004-03-30 | 2010-12-21 | Relypsa, Inc. | Methods and compositions for treatment of ion imbalances |
US8192758B2 (en) | 2004-03-30 | 2012-06-05 | Relypsa, Inc. | Ion binding compositions |
US8282960B2 (en) * | 2004-03-30 | 2012-10-09 | Relypsa, Inc. | Ion binding compositions |
US7556799B2 (en) * | 2004-03-30 | 2009-07-07 | Relypsa, Inc. | Ion binding polymers and uses thereof |
BRPI0616604A2 (pt) * | 2005-09-30 | 2012-12-25 | Ilypsa Inc | mÉtodo para remover e composiÇço para seletivamente remover Íon de potÁssio do trato gastrintestinal de um mamÍfero, mÉtodo para seletivamente remover Íon de potÁssio de um meio-ambiente, composiÇço farmacÊutica, partÍcula de nécleo-envoltàrio, e, usos de uma partÍcula de nécleo-envoltàrio e de uma composiÇço farmacÊutica |
CA2624112A1 (en) * | 2005-09-30 | 2007-04-05 | Ilypsa, Inc. | Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom |
WO2010022380A2 (en) * | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Linear polyol stabilized polyfluoroacrylate compositions |
WO2010022381A1 (en) * | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
US20100111892A1 (en) * | 2008-08-22 | 2010-05-06 | Relypsa, Inc. | Crosslinked polyfluoroacrylic acid and processes for the preparation thereof |
-
2005
- 2005-03-30 CA CA2557848A patent/CA2557848C/en not_active Expired - Fee Related
- 2005-03-30 GB GB0621241A patent/GB2430624B/en not_active Expired - Fee Related
- 2005-03-30 EP EP05731099A patent/EP1732516B1/en not_active Not-in-force
- 2005-03-30 BR BRPI0509366A patent/BRPI0509366B8/pt active IP Right Grant
- 2005-03-30 AU AU2005228696A patent/AU2005228696B2/en not_active Ceased
- 2005-03-30 EP EP05732849A patent/EP1732523B9/en active Active
- 2005-03-30 KR KR1020067022533A patent/KR101153035B1/ko active IP Right Grant
- 2005-03-30 CA CA2557999A patent/CA2557999C/en not_active Expired - Fee Related
- 2005-03-30 DE DE112005000730.8T patent/DE112005000730B4/de active Active
- 2005-03-30 MX MXPA06011270A patent/MXPA06011270A/es active IP Right Grant
- 2005-03-30 EP EP05747062A patent/EP1732524B1/en not_active Not-in-force
- 2005-03-30 WO PCT/US2005/011010 patent/WO2005094384A2/en active Application Filing
- 2005-03-30 JP JP2007506518A patent/JP4964122B2/ja not_active Expired - Fee Related
- 2005-03-30 AU AU2005231424A patent/AU2005231424B2/en active Active
- 2005-03-30 AU AU2005231383A patent/AU2005231383B2/en not_active Ceased
- 2005-03-30 KR KR1020067022589A patent/KR101228233B1/ko active IP Right Grant
- 2005-03-30 BR BRPI0509365A patent/BRPI0509365B8/pt not_active IP Right Cessation
- 2005-03-30 US US11/095,760 patent/US7776319B2/en not_active Expired - Fee Related
- 2005-03-30 WO PCT/US2005/010747 patent/WO2005097072A1/en active Application Filing
- 2005-03-30 GB GB0621244A patent/GB2430368B/en not_active Expired - Fee Related
- 2005-03-30 PL PL05732849T patent/PL1732523T3/pl unknown
- 2005-03-30 BR BRPI0509331A patent/BRPI0509331B8/pt not_active IP Right Cessation
- 2005-03-30 WO PCT/US2005/010978 patent/WO2005097081A1/en active Application Filing
- 2005-03-30 JP JP2007506580A patent/JP4974882B2/ja active Active
- 2005-03-30 KR KR1020067022590A patent/KR101199608B1/ko active IP Right Grant
- 2005-03-30 JP JP2007506295A patent/JP5000480B2/ja not_active Expired - Fee Related
- 2005-03-30 GB GB0621242A patent/GB2430367B/en active Active
- 2005-03-30 CA CA2558029A patent/CA2558029C/en active Active
-
2008
- 2008-03-26 US US12/055,726 patent/US8216560B2/en active Active
- 2008-03-26 US US12/055,765 patent/US8287847B2/en active Active
- 2008-03-26 US US12/055,746 patent/US8282913B2/en active Active
- 2008-09-26 US US12/238,844 patent/US8445014B2/en active Active
-
2010
- 2010-08-16 US US12/857,264 patent/US8409561B2/en active Active
-
2011
- 2011-01-27 US US13/015,134 patent/US8475780B2/en not_active Expired - Lifetime
-
2012
- 2012-10-05 US US13/646,104 patent/US20130272990A1/en not_active Abandoned
- 2012-10-09 US US13/647,894 patent/US8889115B2/en not_active Expired - Lifetime
- 2012-10-09 US US13/647,690 patent/US8778324B2/en not_active Expired - Lifetime
-
2014
- 2014-06-04 US US14/295,950 patent/US20140286891A1/en not_active Abandoned
-
2015
- 2015-12-04 US US14/959,574 patent/US20160082039A1/en not_active Abandoned
-
2016
- 2016-07-14 US US15/210,226 patent/US10485821B2/en not_active Expired - Lifetime
-
2019
- 2019-11-25 US US16/693,800 patent/US20200085856A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0509331B8 (pt) | uso de uma composição de ligação de sódio | |
EA201490822A1 (ru) | Модифицированные полипептиды рецептора активина и их применение | |
ATE372324T1 (de) | Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen | |
BR112018015238A2 (pt) | conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição | |
WO2008043753A8 (en) | Rna antagonist compounds for the modulation of pcsk9 | |
BR112012025568A2 (pt) | proteínas de ligação ao tnf-<244>. | |
EA200702656A1 (ru) | Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение | |
WO2004099171A3 (en) | Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b | |
WO2006055625A3 (en) | Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors | |
NO20054769L (no) | Substituerte fenylalkansyrer | |
WO2009079585A3 (en) | Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins | |
WO2007084986A3 (en) | Compositions and methods for preventing or treating feline chronic kidney disease | |
BRPI0914504B8 (pt) | uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv | |
DE602005020501D1 (de) | Vernetzte aminpolymere | |
WO2008113515A3 (en) | huTNFR1 SELECTIVE ANTAGONISTS | |
EA200901249A1 (ru) | Ингибиторы связывания протеинкиназ | |
BRPI0415781A (pt) | método para o tratamento de diabetes em um paciente e kit farmacêutico | |
ATE453383T1 (de) | Ionenbindende zusammensetzungen | |
WO2005079541A3 (en) | Terephthalamide peptidomimetic compounds and methods | |
EA200701086A1 (ru) | Производные изоксазола, их фармацевтические композиции и способ лечения невропатической боли | |
BRPI1009237A2 (pt) | inibidores de ligação de proteína quinase. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: ILYPSA, INC. (US) Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020120015933/RJ DE 27/02/2012. |
|
B25G | Requested change of headquarter approved |
Owner name: ILYPSA, INC. (US) Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020120016146/RJ DE 27/02/2012. |
|
B25A | Requested transfer of rights approved |
Owner name: RELYPSA, INC. (US) Free format text: TRANSFERIDO DE: ILYPSA, INC. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/11/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2716 DE 24-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |